Marker Therapeutics, Inc. Share Price

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 18/07/2024 BST 5-day change 1st Jan Change
5.51 USD -7.55% Intraday chart for Marker Therapeutics, Inc. +13.14% +0.18%
Sales 2024 * 1.24M 96.1M Sales 2025 * - Capitalization 53.16M 4.11B
Net income 2024 * -21M -1.62B Net income 2025 * -32M -2.47B EV / Sales 2024 * 42.7 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-3.63 x
P/E ratio 2025 *
-4.48 x
Employees 8
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.8%
More Fundamentals * Estimated data
Dynamic Chart

Latest transcript on Marker Therapeutics, Inc.

1 day-7.55%
1 week+13.14%
Current month+1.47%
1 month+19.26%
3 months+34.38%
6 months+27.25%
Current year+0.18%
More quotes
1 week
4.92
Extreme 4.92
5.99
1 month
4.02
Extreme 4.02
5.99
Current year
3.33
Extreme 3.33
5.99
1 year
2.40
Extreme 2.4
9.68
3 years
0.67
Extreme 0.6706
23.80
5 years
0.67
Extreme 0.6706
75.00
10 years
0.67
Extreme 0.6706
205.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 16/10/18
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 59 31/10/19
Members of the board TitleAgeSince
Chairman 63 16/10/18
Director/Board Member 60 05/08/19
Director/Board Member 60 07/12/21
More insiders
Date Price Change Volume
18/07/24 5.51 -7.55% 11 125
17/07/24 5.96 +1.88% 15,133
16/07/24 5.85 +5.03% 24,881
15/07/24 5.57 +6.50% 93,348
12/07/24 5.23 +7.39% 14,451

Delayed Quote Nasdaq, July 18, 2024 at 09:00 pm

More quotes
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.96 USD
Average target price
11 USD
Spread / Average Target
+84.56%
Consensus